ArticleScientific reports2025
Elevated troponin levels in rhabdomyolysis as a predictor of mortality in patients with normal kidney and cardiac function.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analytical Performance of the New Sysmex High-Sensitivity Troponin T Assay.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRhabdomyolysis is characterized by muscle breakdown and the release of myocyte contents into the bloodstream, which can lead to severe complications. Elevated troponin levels, typically a marker of heart muscle injury, have been observed in rhabdomyolysis, but their clinical significance in this context remains unclear. This study aimed to evaluate the association between elevated troponin levels and mortality in patients with rhabdomyolysis, specifically those with normal kidney function and left ventricular function.
methodsThis single-centre, retrospective study was conducted at a tertiary university medical centre from 2010 to 2022. The study included 252 patients diagnosed with rhabdomyolysis, defined by a creatine phosphokinase (CPK) level at least five times the upper normal limit. Patients were stratified into troponin-positive and troponin-negative groups. Only patients with an estimated glomerular filtration rate (eGFR) above 90 ml/min and normal left ventricular function were included. The primary outcome was 90-day survival, with secondary outcomes including 30-day survival and in-hospital mortality.
resultsPatients with elevated troponin levels had significantly higher 90-day mortality rates, longer hospital stays, and were older with more comorbidities compared to the troponin-negative group. These patients had worse outcomes despite lower CPK levels in the troponin-positive group. The receiver operating characteristic (ROC) analysis showed a limited predictive value for CPK levels for troponin positivity.
conclusionsElevated troponin levels in rhabdomyolysis, particularly in older patients, are associated with increased mortality, independent of kidney and left ventricular function. This suggests the need for heightened monitoring and potentially more aggressive management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.